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CASE REPORT
Successful Treatment of Cutaneous Lesions of 
Dermatomyositis with Topical Pimecrolimus
Ji Eun Kim, M.D., Myeong Gil Jeong, M.D., Ha Eun Lee, M.D., Joo Yeon Ko, M.D., Young Suck Ro, M.D.
Department of Dermatology, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Korea
Dermatomyositis (DM) is an idiopathic inflammatory pro-
cess characterized by proximal muscle weakness and 
cutaneous lesions, such as the Gottron’s sign, heliotrope 
rash, and erythematous photosensitive rash. Administration 
of systemic agents for the treatment of underlying systemic 
diseases leads to remission of the cutaneous lesions in many 
cases. However, cutaneous lesions may remain refractory to 
treatment. Pimecrolimus is a calcineurin inhibitor with 
combined anti-inflammatory and immunomodulatory acti-
vity. It has high affinity to the skin and low permeation 
potential, even in patients with acute skin inflammation and 
in those undergoing post-topical corticosteroid therapy. We 
herein report two DM patients whose cutaneous lesions 
were refractory to conventional treatment but showed 
dramatic response to topical pimecrolimus. The clinical 
outcomes suggest that topical pimecrolimus may be a good 
therapeutic alternative for the management of the cutaneous 
lesions of DM. (Ann Dermatol 23(3) 348∼351, 2011)
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INTRODUCTION
Dermatomyositis (DM) is a rare inflammatory myopathy 
associated with characteristic skin lesions and muscular 
weakness
1. Administration of systemic agents, such as 
corticosteroids, hydroxychloroquine, methotrexate, myco-
phenolate mofetil, and/or intravenous immunoglobulins 
for the treatment of myopathy lead in many cases to 
remission of the cutaneous lesions. Nevertheless, cuta-
neous lesions may sometimes exhibit discordant response 
to therapy for myopathy and can continue to be refractory 
to treatment
2.
 
Pimecrolimus is a calcineurin inhibitor with combined 
anti-inflammatory and immunomodulatory activity
3. This 
is the first report topical pimecrolimus was used for the 
treatment mode of cutaneous lesions of DM. We describe 
a patient with classic DM and a patient with clinically 
amyopathic DM (CADM). In both cases, cutaneous lesions 
improved markedly after treatment with topical pime-
crolimus. 
CASE REPORT
Case 1
A 33 year-old woman with DM was referred to our 
dermatologic clinic with an erythematous photosensitive 
rash over her face, neck, hands, shoulder and back. She 
showed the shawl sign (Fig. 1A), and Gottron’s sign (Fig. 
1B). She had been treated with methotrexate (10 mg/week 
p.o.), hydroxychloroquine sulfate (400 mg/day p.o.), 
prednisolone (15 mg/day p.o), and cyclosporin (50 
mg/day p.o.) for the previous 2 months at a rheumatology 
clinic. Despite marked improvement in muscle weakness, 
the cutaneous lesions remained active. As an alternative 
treatment, topical application of pimecrolimus cream 1% 
was attempted over the affected areas twice daily. Four 
months later, she demonstrated good response, especially 
the shawl sign (Fig. 1C), while the Gottron’s sign showed 
mild improvement (Fig. 1D). After ongoing therapy for 
another 6 months, all cutaneous lesions resolved (Fig. 1E, Successful Treatment of DM  with Topical Pimecrolimus
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Fig. 1. (A) Patient 1 with the shawl 
sign before treatment. (B) Gottron’s
sign before treatment. (C, D) Two 
months later after treatment with 
topical pimecrolimus. (E, F) Ten 
months later after treatment with 
topical pimecrolimus.
F), and she stopped applying topical pimecrolimus. 
During a follow-up period of 4 months, there did not 
experience relapse. 
Case 2 
A 43 year-old woman presented with a 5-month history of 
periorbital rash and violaceous papules over her proximal 
interphalangeal and metacarpophalangeal joints (Fig. 2A), 
periungual erythema, and pruritic poikilodermatous ery-
thema on her nape (Fig. 2B) and trunk (Fig. 2C). She had 
no history of muscle weakness. A biopsy specimen obta-
ined from her back reavealed histopathological findings 
compatible with DM. She did not develop muscle 
weakness and had no serum muscle enzyme abnor-
malities for 7 months. Based on the history, laboratory and 
histopathological findings, a diagnosis of CADM was JE Kim, et al
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Fig. 2. (A) Patient 2 with the Gottron’s
sign before treatment. (B) Poikiloder-
matous erythematous patch on the 
nape and trunk before treatment. (C)
Poikilodermatous erythematous patch
on the right flank before treatment. 
(D, E, F) Three months after treat-
ment with topical pimecrolimus. (G, 
H, I) One year later after stopping 
topical pimecrolimus treatment. 
made. She was subsequently treated with methotrexate 
(15 mg/week, p.o.), hydroxychloroquine sulfate (400 
mg/day p.o.), and prednisolone (15 mg/day p.o.), topical 
corticosteroids and sunscreens, and her cutaneous lesions 
temporarily subsided but subsequently showed repetitive 
relapse. Twice daily application of topical pimecrolimus 
cream 1% was initiated. Six months after starting this treat-
ment, the Gottron’s sign on her fingers showed moderate 
improvement (Fig. 2D). Almost all poikilodermatous 
erythematous lesions on her nape and trunk showed 
significant improvement with no associated adverse effects 
(Fig. 2E, F). After 1 year of treatment, the cutaneous lesions 
almost resolved, and topical pimecrolimus treatment was 
subsequently stopped. Throughout a follow-up period of 1 
year after stopping treatment, the cutaneous lesions 
maintained their improvement (Fig. 2G, H, I).Successful Treatment of DM  with Topical Pimecrolimus
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DISCUSSION
DM is an idiopathic inflammatory process manifested by 
proximal muscle weakness and characteristic cutaneous 
lesions. The term classic DM refers to the concurrence of 
myositis resulting in clinically significant proximal muscle 
weakness and hallmark inflammatory skin lesions de-
veloped in specific anatomical distribution. On the con-
trary, CADM solely describes hallmark cutaneous mani-
festations of DM for prolonged periods (6 months or 
longer) without clinically evident muscle weakness
4.
Cutaneous lesions may be the major manifestation of 
DM
1. Nevertheless, cutaneouslesions of DM are some-
times refractory to several therapeutic modalities
2. Dawkins 
et al.
2 examined 35 patients, and found that 15 of them 
experienced resistant cutaneous lesions despite reduction 
in their muscle disease by oral corticosteroids and 
anti-malarials, followed by oral methotrexate. 
Calcineurin inhibitors such as pimecrolimus and tacro-
limus mainly inhibit the action of calcineurin. They act by 
binding to isomerase macrophilin 12 to form complexes 
that block serine-threonine phosphatase calcineurin, a 
protein that physiologically dephosphorylates, and thereby 
activates, the cytoplasmic subunits of the nuclear factor of 
the activated T cells (NF-AT). Thus, NF-AT cannot enter 
the nucleus to form a complex with the nuclear subunit, 
and therefore cannot interact with the promoter regions of 
many cytokine genes, including interleukin-2 (IL-2), a key 
regulator of T cell proliferation and differentiation, and 
others such as IL-3, IL-4, IL-5, interferon γ, and TNF-α
3,5. 
Pimecrolimus is an ascomycin immunomodulating macro-
lactam. The pharmacologic activity of pimecrolimus is 
known to be more selective than that of tacrolimus, 
because it does not affect the differentiation, maturation or 
functions of Langerhans cells and does not induce apop-
tosis
6. In addition, pimecrolimus is more lipophilic than 
tacrolimus, therefore it has higher affinity to the skin and 
lower permeation potential
3,7. Pimecrolimus cream has 
been shown to be effective in several cutaneous inflam-
matory diseases, such as atopic dermatitis, inverse psor-
iasis, vitiligo, oral lichen planus, and recently, cutaneous 
lupus eyrthematosus
8,9. Although topical tacrolimus has 
been successfully used in the treatment of cutaneous 
lesions of DM, as have been reported since 2002
10, there 
has been no report on topical pimecrolimus treatment of 
cutaneous lesions of DM.  
We used topical pimecrolimus to treat cutaneous lesions 
of classic DM and CADM for the first time, and witnessed 
remarkable improvement in the poikilodermatous ery-
thema on the trunk and the photosensitive rash on the 
face. The clinical outcomes suggest that topical pimecrolimus 
may be an efficacious alternative for the management of 
cutaneous lesions of DM. However, careful long-term 
follow-up is mandatory in these patients, and controlled 
clinical trials are warranted to validate our findings.
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